Furthermore, combined inhibition by a dual EGFR/HER-2/neu inhibitor (canertinib) and a HGFR inhibitor (PHA665752) resulted in a decreased ovarian cancer cell proliferation [46,47]. Here, MET is linked to ovarian cancer.